BWA
NTLA icon

Basecamp Wealth Advisors’s Intellia Therapeutics NTLA Stock Holding History

Basecamp Wealth Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34 Sell
2
-13
-87% -$182 ﹤0.01% 1816
2026
Q1 		$192 Buy
+15
New +$191 ﹤0.01% 1867

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Basecamp Wealth Advisors's NTLA Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its Intellia Therapeutics (NTLA) stake by 87% in Q2 2026, selling an estimated $182 and leaving 2 shares worth $34. The position accounts for ﹤0.01% of the portfolio, ranked #1816.

Basecamp Wealth Advisors first reported a position in NTLA in Q1 2026 and has held it in 2 quarters since. The position peaked at $192 in Q1 2026. 327 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Basecamp Wealth Advisors held 2 shares of Intellia Therapeutics worth $34 as of Q2 2026.
  • Basecamp Wealth Advisors sold 13 Intellia Therapeutics shares in Q2 2026, an estimated $182.
  • Intellia Therapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1816 holding.
  • Basecamp Wealth Advisors first reported a position in Intellia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Basecamp Wealth Advisors's Intellia Therapeutics position peaked at $192 in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.